{"id":22737,"date":"2025-10-30T03:00:00","date_gmt":"2025-10-30T07:00:00","guid":{"rendered":"https:\/\/dbv-technologies.com\/press_releases\/dbv-technologies-participe-au-congres-scientifique-annuel-de-lacaai\/"},"modified":"2025-10-30T03:00:00","modified_gmt":"2025-10-30T07:00:00","slug":"dbv-technologies-participe-au-congres-scientifique-annuel-de-lacaai","status":"publish","type":"press_releases","link":"https:\/\/dbv-technologies.com\/fr\/press_releases\/dbv-technologies-participe-au-congres-scientifique-annuel-de-lacaai\/","title":{"rendered":"DBV Technologies participe au congr\u00e8s scientifique annuel de l&rsquo;ACAAI"},"content":{"rendered":"<div class=\"pr-date-globe\">October 30, 2025 03:00 ET<\/div>\n<p align=\"right\">Ch\u00e2tillon, France, le 30 octobre 2025 <\/p>\n<p align=\"justify\"><strong>DBV Technologies participe au congr\u00e8s scientifique annuel de l&rsquo;ACAAI <\/strong><\/p>\n<p align=\"justify\">DBV Technologies &lpar;Euronext : DBV \u2013 ISIN : FR0010417345 \u2013 Nasdaq Stock Market : DBVT \u2013 CUSIP : 23306J309) une soci\u00e9t\u00e9 biopharmaceutique en phase clinique, a annonc\u00e9 sa participation au congr\u00e8s scientifique annuel 2025 de l&rsquo;American College of Allergy, Asthma &amp; Immunology &lpar;ACAAI), qui se tiendra du 6 au 10 novembre \u00e0 Orlando, en Floride.<\/p>\n<p align=\"justify\">DBV organisera un forum produit intitul\u00e9 \u00ab <strong>Harnessing Immune Plasticity to Alter the Path of Food Allergy<\/strong> \u00bb &lpar;Tirer parti de la plasticit\u00e9 immunitaire afin d\u2019infl\u00e9chir l\u2019\u00e9volution des allergies alimentaires). Un panel d\u2019allergologues de renomm\u00e9e internationale \u2014 les Drs Gideon Lack, Hugh Sampson, George du Toit, Kirsten Perrett et Matthew Greenhawt \u2014 discutera des donn\u00e9es immunologiques et cliniques soutenant les b\u00e9n\u00e9fices d\u2019une intervention pr\u00e9coce dans la prise en charge des allergies alimentaires. Lors de la pr\u00e9sentation, le Dr Perrett d\u00e9taillera un essai clinique de phase 2 planifi\u00e9 dans lequel DBV \u00e9valuera l\u2019efficacit\u00e9 et l\u2019innocuit\u00e9 du patch VIASKIN<sup>\u00ae<\/sup> Peanut pour atteindre une consommation ad libitum d\u2019arachide chez des nourrissons \u00e2g\u00e9s de 6 \u00e0 12 mois allergiques \u00e0 l\u2019arachide, apr\u00e8s un minimum de 3 ans de traitement.<\/p>\n<p align=\"justify\"><strong>Information sur le forum produit :<\/strong><\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify;\"><strong>Date :<\/strong> Samedi 8 novembre 2025<\/li>\n<li style=\"text-align:justify;\"><strong>Heure :<\/strong> 11 h 35 \u00e0 13 h 00 &lpar;heure de l&rsquo;Est)<\/li>\n<li style=\"margin-bottom:12pt; text-align:justify;\"><strong>Lieu :<\/strong> Hall Ouest E\n<\/li>\n<\/ul>\n<p align=\"justify\"><em>\u00ab Nous commen\u00e7ons \u00e0 observer un changement vers une approche plus proactive de la prise en charge des allergies alimentaires, tant en ce qui concerne l\u2019introduction pr\u00e9coce des allerg\u00e8nes potentiels que l\u2019utilisation d\u2019interventions immunomodulatrices \u00bb, <\/em>d\u00e9clare le <strong>Dr Gideon Lack<\/strong>, <strong>professeur d\u2019allergologie p\u00e9diatrique au London Allergy Care and Knowledge <\/strong>et co-investigateur principal de l\u2019essai clinique de phase 2 sur l\u2019intervention pr\u00e9coce.<em> \u00ab Avec cette \u00e9tude \u00e0 venir, nous avons d\u00e9sormais l\u2019opportunit\u00e9 d\u2019examiner si une intervention plus pr\u00e9coce avec le patch VIASKIN<sup>\u00ae<\/sup> Peanut &#8211; immunoth\u00e9rapie susceptible de modifier l\u2019\u00e9volution de la maladie &#8211; peut permettre d\u2019atteindre une consommation ad libitum d\u2019arachide chez des enfants \u00e2g\u00e9s de 6 \u00e0 12 mois. \u00bb<\/em><\/p>\n<p align=\"justify\">Le congr\u00e8s de cette ann\u00e9e comprendra \u00e9galement une pr\u00e9sentation du Dr Matthew Greenhawt sur les r\u00e9sultats finaux de l\u2019extension en ouvert de l\u2019\u00e9tude EPITOPE &lpar;EPOPEX), dans le cadre de la session \u00ab <strong>Distinguished Industry and Late-breaking Oral Abstract <\/strong>\u00bb.<\/p>\n<p align=\"justify\">\u00ab <em>Avec notre forum produit annon\u00e7ant une \u00e9tude de phase 2 in\u00e9dite visant \u00e0 \u00e9valuer si le patch VIASKIN<sup>\u00ae<\/sup> Peanut peut permettre une consommation ad libitum, et des r\u00e9sultats finaux convaincants issus des trois ann\u00e9es de l\u2019\u00e9tude EPOPEX, notre pr\u00e9sence au congr\u00e8s de cette ann\u00e9e illustre notre travail et notre engagement aupr\u00e8s de la population p\u00e9diatrique de la communaut\u00e9 des allergies alimentaires \u00bb, <\/em>a d\u00e9clar\u00e9 le <strong>Dr Pharis Mohideen,<\/strong> <strong>Directeur M\u00e9dical de DBV Technologies<\/strong>.<em> \u00ab Au-del\u00e0 des efforts cliniques mis en \u0153uvre par DBV pour cette population de patient plus jeune, nous travaillons au d\u00e9p\u00f4t potentiel du BLA pour le patch VIASKIN<sup>\u00ae<\/sup> Peanut destin\u00e9 aux enfants \u00e2g\u00e9s de 1 \u00e0 3 ans au cours du second semestre de l\u2019ann\u00e9e prochaine, dans le cadre d\u2019une proc\u00e9dure d\u2019Approbation Acc\u00e9l\u00e9r\u00e9e, comme convenu pr\u00e9c\u00e9demment avec la FDA<\/em>. \u00bb<\/p>\n<p align=\"justify\"><strong>Pr\u00e9sentation scientifique orale : <\/strong><\/p>\n<ul type=\"disc\">\n<li style=\"text-align:left;\">\u00ab <strong>Long-Term Efficacy and Safety of Epicutaneous Immunotherapy in Peanut-Allergic Toddlers: EPOPEX End-of-Study Results <\/strong>\u00bb sera pr\u00e9sent\u00e9 par Dr Matthew Greenhawt<\/li>\n<li style=\"text-align:left;\"><strong>Session : <\/strong>Distinguished Industry &amp; Late-breaking Oral Abstracts &#8211; Session 2<\/li>\n<li style=\"text-align:left;\"><strong>Date<\/strong> <strong>:<\/strong> samedi 8 novembre 2025&nbsp;&nbsp; <\/li>\n<li style=\"text-align:left;\"><strong>Heure de la session<\/strong> <strong>:<\/strong> 16 h 30 \u00e0 18 h 00 &lpar;heure de l&rsquo;Est)<\/li>\n<li style=\"text-align:left;\"><strong>Heure de la pr\u00e9sentation :<\/strong> 16 h 43 &lpar;heure de l&rsquo;Est)<\/li>\n<li style=\"margin-bottom:12pt; text-align:left;\"><strong>Lieu :<\/strong> Salle W231<\/li>\n<\/ul>\n<p align=\"justify\">La soci\u00e9t\u00e9 sera pr\u00e9sente au <strong>stand n\u00b0 711<\/strong> et sponsorise le <strong>34e FIT Bowl\u2122<\/strong> annuel, une comp\u00e9tition de type jeu t\u00e9l\u00e9vis\u00e9 qui teste les connaissances en mati\u00e8re d&rsquo;allergie, d&rsquo;asthme et d&rsquo;immunologie des \u00e9quipes participantes issues de programmes de formation dans tout le pays. La comp\u00e9tition aura lieu le samedi 8 novembre, de 17 h 45 \u00e0 19 h 45 &lpar;heure de l&rsquo;Est).<\/p>\n<p align=\"justify\"><strong>\u00c0 propos de DBV Technologies<\/strong><br \/>DBV Technologies est une entreprise biopharmaceutique de stade clinique sp\u00e9cialis\u00e9e dans le d\u00e9veloppement d\u2019options de traitement des allergies alimentaires et autres affections immunologiques ayant d\u2019importants besoins m\u00e9dicaux non satisfaits. DBV Technologies se concentre actuellement sur l\u2019\u00e9tude de l\u2019utilisation de sa technologie exclusive, le patch VIASKIN\u00ae, pour traiter les allergies alimentaires caus\u00e9es par une r\u00e9action immunitaire hypersensible et caract\u00e9ris\u00e9es par une gamme de sympt\u00f4mes dont la gravit\u00e9 varie de l\u00e9g\u00e8re \u00e0 l\u2019anaphylaxie potentiellement mortelle. Des millions de personnes vivent avec des allergies alimentaires, y compris de jeunes enfants. Gr\u00e2ce \u00e0 l\u2019immunoth\u00e9rapie \u00e9picutan\u00e9e &lpar;EPIT), le patch VIASKIN\u00ae&nbsp;est con\u00e7u pour dispenser des quantit\u00e9s de microgrammes d\u2019un compos\u00e9 biologiquement actif dans le syst\u00e8me immunitaire \u00e0 travers une peau intacte. L\u2019EPIT est une nouvelle classe de traitement non invasif cherchant \u00e0 modifier l\u2019allergie sous-jacente d\u2019un individu en r\u00e9\u00e9duquant le syst\u00e8me immunitaire \u00e0 se d\u00e9sensibiliser \u00e0 l\u2019allerg\u00e8ne en tirant parti des propri\u00e9t\u00e9s de tol\u00e9rance immunitaire de la peau. DBV Technologies s\u2019est engag\u00e9e \u00e0 transformer le traitement des personnes souffrant d\u2019allergies alimentaires. Les programmes d\u2019allergie alimentaire de la Soci\u00e9t\u00e9 comprennent des \u00e9tudes cliniques en cours avec le patch VIASKIN\u00ae&nbsp;peanut chez les jeunes enfants &lpar;de 1 \u00e0 3 ans) et les enfants &lpar;de 4 \u00e0 7 ans) allergiques \u00e0 l\u2019arachide.<\/p>\n<p align=\"justify\">Le si\u00e8ge mondial de DBV Technologies est situ\u00e9 \u00e0 Ch\u00e2tillon, en France, avec des op\u00e9rations nord-am\u00e9ricaines bas\u00e9es \u00e0 Warren, dans le New Jersey. Les actions ordinaires de la Soci\u00e9t\u00e9 sont n\u00e9goci\u00e9es sur le segment B d\u2019Euronext Paris &lpar;symbole : DBV, code ISIN : FR0010417345) et les ADS de la Soci\u00e9t\u00e9 &lpar;repr\u00e9sentant chacun cinq actions ordinaires) sont n\u00e9goci\u00e9s sur le Nasdaq Capital Market &lpar;DBVT \u2013 CUSIP : 23306J309).<\/p>\n<p align=\"justify\">Pour plus d\u2019informations, veuillez consulter&nbsp;<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=o8UnUm23OJAADWsTxWk0k3gN6DnRNPUF9ALwJTCzSilv7Y92dcE9AnF63TKaRxCqPhYZ8gvHCP0Hbx0MExyftcfu-4E2WsWXQt8xH_DrGWIIDsb5nno9k3Q0p2FDkWo0Bxd3VN8pTxMDkyNTGY_2PnXgPt0jBsVZIab0SguZ9ligBUXZhjWxwxFhGIk_EzHzcGB2a4s0ad2RQFhXacySNvY-EHnJOGomluCbbWFYYCu-w0eMlMAXc7i8bdwxaHvuAX97a0-SpeZxOxGKPlofmH-39Y1XzCBVSc6JROeIl3rhAEZ--sYgkoc82t3NZ6nf\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>www.dbv-technologies.com<\/u><\/a>&nbsp;et nous contacter sur&nbsp;<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Z3nF3TP3v2Kb-SPvPBh4eWREzgcBGNDJUm0dmPn8V8qs1p8ecfgqGhQFB30xMFY-zmHoAOm_RG4M5olLaqmsK-MgnhuKv2ihPviEG98cGODxggVJxiFgSXjpGbD_UKa8EiwvcvZWunsRCiMz5MPjMu43dl9KUP4SFqQzNoe_Z9hcEAmwXfyjv48i1AsH4M57e4pnmqWwmmxL39gdGd_IdkWDpfIETGzsRVNtOJ3qYRAYp8LhyuySUsQ-HjIag2cLkNw_iz8bJLBBzPZpSVHzBXKcCYN1OqKqrOOAB8Boq-320NHG3REVLavAnQ3_jujZ\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>X &lpar;anciennement Twitter)<\/u><\/a>&nbsp;et&nbsp;<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=SiWiT_fR1TWfUBWGfN-HqUuYJgFc9AeYuS8g2BGNFIt-fB5ndhQle2MWX6eB2eptjaZdMk6hWI0Z6bB0jYG2-L01a19PVOB6H6uXFCl2-Vu5-Vs13JykCQ4ktbkJ-UtSGb4VFakOpOEL-hpbiKkA8_GaWxO07g35pkyUxL21G03Eh4n_imdtLwyyPJPGh3mc8036Nf8sanZKOfqvagWEDZ7JBwRnGlY1pKRbqXlU-uYrEg8WvaJADPwyQStTNyeamBimWNnFrP7o6Uzu6TTlq8PjiO4Y0AIXXMAHrY935MQ=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><u>LinkedIn.<\/u><\/a> <\/p>\n<p align=\"justify\">VIASKIN est une marque d\u00e9pos\u00e9e de DBV Technologies.<\/p>\n<p align=\"left\"><strong>Contact avec les investisseurs<\/strong><br \/>Katie Matthews<br \/>DBV Technologies<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MzJNzFZELAGJmpCGbugwqoABq-HfiN-bDRxasaLddI7VF9AyE94ZTY0bh_YUPUuDjRx_8dWGiGqTuehM1Wm62AuXNWDXe4S0rdWHttsTz-Bo9ueMlmOWqH2cMd8J4nnmFdwUf-8EZISIjbsWF1lyTQ==\" rel=\"nofollow\" target=\"_blank\" title=\"katie.matthews@dbv-technologies.com\">katie.matthews@dbv-technologies.com<\/a><\/p>\n<p align=\"left\"><strong>Contact avec les m\u00e9dias<\/strong><br \/>Brett Whelan<br \/>DBV Technologies<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7dJAtKa_eVe99EHYwANnlFdIb3srMUW1AheSNzXIMUtJ0QbKy-YSAlzLSPTcb8l74LvlE3zMlowJLAxZ2C1mWPjt3URaxpxqVvqXzMGabe3cIfrd9fWc1CSqmp10egN1REHKFkcWCXMFxpD6IlGweQ==\" rel=\"nofollow\" target=\"_blank\" title=\"brett.whelan@dbv-technologies.com\">brett.whelan@dbv-technologies.com<\/a><\/p>\n<p id=\"gnw_attachments_section-header\">    <strong>Pi\u00e8ce jointe<\/strong><\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>        <a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=Do1kPQPKM7gmLVkn0LxpL8maTZnYdLthHiG9njFtswUGwwZmlAClc7AZhl2WDqw3pgBopbpF5G9luHzUDMqO-BdqqtbvGJZXNyoLQ_zoeKB4TJ7wL9xYXzPTz2Tj1h5b2ISkfFdXnpRpsh3eBrqjSHI0YHrI6DSIaMDBPc8qMcM=\" title=\"version PDF\" rel=\"nofollow\">version PDF<\/a>      <\/li>\n<\/ul>\n<p><img decoding=\"async\" alt=\"\" data-src=\"https:\/\/ml-eu.globenewswire.com\/media\/Y2ZhYjI3MDktMTRkOS00ZDJhLThjMjUtZDc3M2VhNmU1YzhkLTEwMTExNTItMjAyNS0xMC0zMC1mcg==\/tiny\/DBV-Technologies-S-A-.png\" referrerpolicy=\"no-referrer-when-downgrade\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\">            <\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"wds_primary_press_release_type":0,"footnotes":""},"press_release_type":[],"class_list":["post-22737","press_releases","type-press_releases","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/22737","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases"}],"about":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/types\/press_releases"}],"version-history":[{"count":0,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_releases\/22737\/revisions"}],"wp:attachment":[{"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/media?parent=22737"}],"wp:term":[{"taxonomy":"press_release_type","embeddable":true,"href":"https:\/\/dbv-technologies.com\/fr\/wp-json\/wp\/v2\/press_release_type?post=22737"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}